[1] Article Title: The prevalence of hereditary neuromuscular disorders in Northern Norway
	•	Line(s): 2, 5
	•	Section: Title page, Header
	•	Quote(s):
	•	“The prevalence of hereditary neuromuscular disorders in Northern Norway”

⸻

[2] Publication Year: 2021
	•	Line(s): 2
	•	Section: Header
	•	Quote(s):
	•	“Brain and Behavior. 2021;11:e01948.”

⸻

[3] Region: Europe
	•	Line(s): 6
	•	Section: Affiliations
	•	Quote(s):
	•	“University Hospital of North Norway, Tromsø, Norway”

⸻

[4] Country: Norway
	•	Line(s): 6
	•	Section: Affiliations
	•	Quote(s):
	•	“University Hospital of North Norway, Tromsø, Norway”

⸻

[5] Coverage Area: Regional
	•	Line(s): 37, 198
	•	Section: Abstract, Discussion
	•	Quote(s):
	•	“…point prevalence of hereditary neuromuscular disorders on January 1, 2020 in Northern Norway.”

⸻

[6] Study Design: Retrospective
	•	Line(s): 198
	•	Section: Discussion
	•	Quote(s):
	•	“we identified 542 patients with HNMD, giving a total prevalence of 111.9/100,000.”

⸻

[7] Study Population: Patients with hereditary neuromuscular disorders in Northern Norway
	•	Line(s): 63–72
	•	Section: Methods
	•	Quote(s):
	•	“Patients included in this study are children and adults with: … all types of hereditary distal myopathies …”

⸻

[8] Population Characteristics:
	•	Line(s): 134–135
	•	Section: Results
	•	Quote(s):
	•	“…including 95,182 children <18 years old… The population consisted of 237,985 (49.1%) females and 246,561 (50.9%) males.”

⸻

[9] Data Source Type: Clinical records and registries
	•	Line(s): 60–63
	•	Section: Methods
	•	Quote(s):
	•	“We collected information from the electronic patient hospital records… the Norwegian registry of hereditary and congenital neuromuscular disorders… and medical genetics records.”

⸻

[10] Data Source Details: EPR (DIPS ASA), national registries, medical genetics databases
	•	Line(s): 60–63
	•	Section: Methods
	•	Quote(s):
	•	“…electronic patient hospital records (EPR) of Northern Norway (DIPS ASA, Bodø)… Norwegian registry… registry at the Medical genetics department at UNN.”

⸻

[11] Study Timeline Type: Retrospective
	•	Line(s): 38, 66
	•	Section: Abstract, Methods
	•	Quote(s):
	•	“From January 1, 1999, until January 1, 2020, we screened medical and genetic hospital records…”

⸻

[12] Number of Sites: Multiple
	•	Line(s): 62
	•	Section: Methods
	•	Quote(s):
	•	“…UNN, Finnmark Hospital Trust, Nordland Hospital Trust and Helgeland Hospital Trust…”

⸻

[13] Study Start Year: January 1, 1999
	•	Line(s): 38
	•	Section: Abstract
	•	Quote(s):
	•	“From January 1, 1999…”

⸻

[14] Study End Year: January 1, 2020
	•	Line(s): 38
	•	Section: Abstract
	•	Quote(s):
	•	“…until January 1, 2020…”

⸻

[15] Main Ethnicity: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s):
	•	NR

⸻

[16] Ethnicity Details: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s):
	•	NR

⸻

[17] Disease Studied: Hereditary neuromuscular disorders (HNMD), including specific subtypes
	•	Line(s): 70–72
	•	Section: Methods
	•	Quote(s):
	•	“Spinal muscular atrophy type I–IV… Duchenne… LGMD… CMT… MC… etc.”

⸻

[18] Diagnosis Method: Clinical examination, EMG, neurography, biopsy, genetic testing
	•	Line(s): 75–78
	•	Section: Methods
	•	Quote(s):
	•	“…neurologic examination. Except for two patients… all patients had abnormalities on either electromyography (EMG), neurography, muscle biopsy or genetic tests…”

⸻

[19] Diagnosis Criteria Details: Specialist confirmation + abnormal test findings
	•	Line(s): 75–78
	•	Section: Methods
	•	Quote(s):
	•	“…hereditary neuromuscular diagnosis by either a neurologist, a pediatrician or a geneticist… abnormalities on either electromyography (EMG), neurography, muscle biopsy or genetic tests…”

⸻

[20] Disease Phase: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s):
	•	NR

⸻

[21] Cohort Age Group: Mixed
	•	Line(s): 136
	•	Section: Results
	•	Quote(s):
	•	“…95,182 children <18 years old… and 389,364 adults (≥18 years old).”

⸻

[22] Female % in Cohort: 46.5%
	•	Line(s): 138
	•	Section: Results
	•	Quote(s):
	•	“…included 252 (46.5%) females and 290 (53.5%) males.”

⸻

[23] Consanguinity: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s):